Glioblastoma multiforme, diagnosis and treatment; Recent literature review

Ron Batash, Noam Asna, Pamela Schaffer, Nicole Francis, Moshe Schaffer

Research output: Contribution to journalReview articlepeer-review

285 Scopus citations


Background: Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor, with an incidence of 3.19 cases per 100, 000 person years and remarkably poor prognosis showing a 5-year survival rate of 4-5%, and only a 26-33% survival rate at 2 years in clinical trials. Objective: In this paper, we review the different types of treatment modalities based on the relevant databases. Methods of diagnosis will be described briefly. Method: Systemic compilation of the relevant literature. Results & Conclusion: Today's treatments cannot cure GBM patients but only extend their overall survival. The use of chemoradiation, immunotherapy, and radio sensitizers as an adjuvant therapy cannot reduce the high rates of recurrence within a few months after treatment. Radiotherapy will remain the backbone of the treatment but new treatment modalities must be developed.

Original languageEnglish
Pages (from-to)3002-3009
Number of pages8
JournalCurrent Medicinal Chemistry
Issue number27
StatePublished - 1 Aug 2017


  • Biologic agent
  • Chemotherapy
  • Glioblastoma multiforme
  • Immunotherapy
  • Radiation therapy
  • Vaccination

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Organic Chemistry


Dive into the research topics of 'Glioblastoma multiforme, diagnosis and treatment; Recent literature review'. Together they form a unique fingerprint.

Cite this